Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

NCT03178851 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

155

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

BIOLOGICAL: Atezolizumab
DRUG: Cobimetinib
BIOLOGICAL: Atezolizumab
BIOLOGICAL: Atezolizumab

Sponsor

Hoffmann-La Roche